Q3 25 EPS
$0.15
MISS 3.23%
Est. $0.16
Q3 25 Revenue
$134.2M
BEAT +2.83%
Est. $130.5M
vs S&P Since Q3 25
-51.7%
TRAILING MARKET
ADMA -42.3% vs S&P +9.4%
Market Reaction
Did ADMA Beat Earnings? Q3 2025 Results
ADMA Biologics delivered a mixed but broadly constructive third quarter, posting revenue of $134.22 million for Q3 2025, a 12.0% year-over-year gain that cleared the consensus estimate of $130.53 million by 2.83%, even as earnings came in marginally … Read more ADMA Biologics delivered a mixed but broadly constructive third quarter, posting revenue of $134.22 million for Q3 2025, a 12.0% year-over-year gain that cleared the consensus estimate of $130.53 million by 2.83%, even as earnings came in marginally short. Diluted GAAP EPS of $0.15 missed the $0.15 consensus by 3.23%, with the gap explained largely by a sharply higher tax provision of $11.09 million compared to just $840,000 in the year-ago period, along with a $2.18 million debt extinguishment charge tied to a refinancing. The revenue strength was driven by record utilization of ASCENIV, the company's differentiated immunoglobulin therapy, which also supported gross margin expansion to 56.3% from 49.8%, aided by yield-enhanced production batches the FDA recently cleared for commercial release. Management raised FY 2025 revenue guidance to at least $510.00 million and lifted FY 2026 revenue guidance to at least $630.00 million, while projecting total annual revenue exceeding $1.10 billion by FY 2029, underscoring confidence in sustained commercial momentum and margin improvement through the coming years.
Key Takeaways
- • Continued adoption and utilization of ASCENIV by physicians, payers, and patients
- • More favorable mix of higher-margin immunoglobulin sales
- • Operational efficiencies reducing manufacturing costs
- • Yield-enhanced production batches received FDA lot release, expected to drive margin expansion starting Q4 2025
ADMA YoY Financials
Q3 2025 vs Q3 2024, source: SEC Filings
ADMA Revenue by Segment
With YoY comparisons, source: SEC Filings
“ADMA is executing from a position of strength as we enter our next phase of disciplined, profitable growth. The FDA lot release of our first yield‑enhanced production batches marks a pivotal milestone expected to drive sustained gross margin expansion beginning in the fourth quarter of 2025 and through 2026 and beyond. Record ASCENIV utilization and ongoing constructive negotiations with payers for enhanced 2026 reimbursement and access underscore the durable and growing demand for our differentiated plasma‑derived biologics portfolio.”
— Adam Grossman, Q3 2025 Earnings Press Release
ADMA Earnings Trends
ADMA vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
ADMA EPS Trend
Earnings per share: estimate vs actual
ADMA Revenue Trend
Quarterly revenue: estimate vs actual
ADMA Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 MISS | $0.20 | $0.19 | -5.00% | $114.5M | -18.20% |
| Q4 25 BEAT FY | $0.20 | $0.20 | +0.00% | $139.2M | -0.46% |
| FY Full Year | — | $0.60 | — | $510.2M | — |
| Q3 25 MISS | $0.16 | $0.15 | -3.23% | $134.2M | +2.83% |
| Q2 25 BEAT | $0.14 | $0.14 | +3.70% | $122.0M | +0.18% |
| Q1 25 MISS | $0.13 | $0.11 | -15.38% | $114.8M | -1.37% |